Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quality DNA and RNA data, and empower clinicians to make informed, data-driven treatment decisions. 

“Tempus is proud to once again join the oncology research community at AACR and present our research demonstrating the value of multi-dimensional data in advancing personalized cancer care,” said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus. 

Poster presentation details: 

• Poster Title: 62/23 – Temporal concordance rates of pathogenic variants in liquid biopsies taken after solid tissue NGS profiling in a real-world pan-cancer cohort
  • Track: Molecular/Cellular Biology and Genetics
  • Session Data and Time: April 10, 2022, 1:30 PM – 5:00 PM 
  • Overview: This is one of the largest studies analyzing the concordance between solid tissue and cfDNA NGS amongst stage IV patients with breast, colorectal, non-small cell lung cancer,  pancreatic, and prostate cancer. When analyzing patients with pathogenic variants identified in both assays, the study reported that cfDNA identified 86% of solid tissue variants when samples were taken within two weeks of each other and this value decreased as time between assays increased to beyond 365 days. Across all time points studied, 44% of patients had additional variants identified in cfDNA which were not found in solid tumor profiling alone. 

• Poster Title: 766/22 – Genomic and transcriptomic comparison between breast cancer patients of African and European ancestries demonstrates potential for biomarker-informed therapies
  • Track: Molecular/Cellular Biology and Genetics
  • Session Data and Time: April 11, 2022, 9:00 AM – 12:30 PM 
  • Overview: This study sought to compare the genomic and transcriptomic differences between breast cancer tumors from African ancestry and European ancestry patients, stratified by breast cancer subtype and clinical stage in a real-world cohort. In HR+/HER2- and triple-negative breast cancers, significant differences in mutational spectrums and gene expression between genetically determined African and European ancestries were observed. Notably, TP53 and KMT2C were more prevalent in patients of African ancestry,  while PIK3CA was more prevalent in patients of European ancestry.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.